RT Journal Article
SR Electronic
T1 Factors associated with the decay of anti-SARS-CoV-2 neutralizing antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated (BBV152) vaccine in Chennai, India: a prospective, longitudinal, cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.26.22271097
DO 10.1101/2022.02.26.22271097
A1 Selvavinayagam, Sivaprakasam T
A1 Yong, Yean Kong
A1 Tan, Hong Yien
A1 Zhang, Zhong-Ying
A1 Subramanian, Gurunathan
A1 Rajeshkumar, Manivannan
A1 Vasudevan, Kalaivani
A1 Jayapal, Priyanka
A1 Narayanasamy, Krishnasamy
A1 Ramesh, Dinesh
A1 Palani, Sampath
A1 Larsson, Marie
A1 Esaki M, Shankar
A1 Raju, Sivadoss
YR 2022
UL http://medrxiv.org/content/early/2022/02/27/2022.02.26.22271097.abstract
AB Background The magnitude of protection conferred after recovery from COVID-19 or by vaccine administration, and the duration of protective immunity developed, remains ambiguous.Methods We investigated the factors associated with antibody decay in 519 individuals who received treatment for COVID-19-related illness or received COVID-19 vaccination with two commercial vaccines, viz., an adenoviral vector-based (AZD1222) and a whole-virion-based inactivated (BBV152) vaccine in Chennai, India from March 2021. Blood samples collected during regular follow-up post-infection/vaccination andwere examined for anti-SARS-CoV-2 IgG by a commercial automated chemiluminescent immunoassay (CLIA).Results Age and underlying comorbidities were the two variables that were independently associated with the development of breakthrough infection. Individuals who were >60 years of age with underlying comorbid conditions had a ∼15 times and ∼10 times greater risk for developing a breakthrough infection and hospitalization, respectively. The time elapsed since the first booster dose was associated with attrition in anti-SARS-CoV-2 IgG, where each month passed was associated with an ebb in the neutralizing antibody levels by a coefficient of -6 units.Conclusions Our findings advocate that the elderly with underlying comorbidities require a second booster dose with AZD1222 and BBV152.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Human Ethics Committee of the Madras Medical College (EC No. 03092021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors